Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Oct 6;163(7):507-18.
doi: 10.7326/M14-2768.

Cumulative Incidence of Cancer Among Persons With HIV in North America: A Cohort Study

Collaborators

Cumulative Incidence of Cancer Among Persons With HIV in North America: A Cohort Study

Michael J Silverberg et al. Ann Intern Med. .

Abstract

Background: Cancer is increasingly common among persons with HIV.

Objective: To examine calendar trends in cumulative cancer incidence and hazard rate by HIV status.

Design: Cohort study.

Setting: North American AIDS Cohort Collaboration on Research and Design during 1996 to 2009.

Participants: 86 620 persons with HIV and 196 987 uninfected adults.

Measurements: Cancer type-specific cumulative incidence by age 75 years and calendar trends in cumulative incidence and hazard rates, each by HIV status.

Results: Cumulative incidences of cancer by age 75 years for persons with and without HIV, respectively, were as follows: Kaposi sarcoma, 4.4% and 0.01%; non-Hodgkin lymphoma, 4.5% and 0.7%; lung cancer, 3.4% and 2.8%; anal cancer, 1.5% and 0.05%; colorectal cancer, 1.0% and 1.5%; liver cancer, 1.1% and 0.4%; Hodgkin lymphoma, 0.9% and 0.09%; melanoma, 0.5% and 0.6%; and oral cavity/pharyngeal cancer, 0.8% and 0.8%. Among persons with HIV, calendar trends in cumulative incidence and hazard rate decreased for Kaposi sarcoma and non-Hodgkin lymphoma. For anal, colorectal, and liver cancer, increasing cumulative incidence, but not hazard rate trends, were due to the decreasing mortality rate trend (-9% per year), allowing greater opportunity to be diagnosed. Despite decreasing hazard rate trends for lung cancer, Hodgkin lymphoma, and melanoma, cumulative incidence trends were not seen because of the compensating effect of the declining mortality rate.

Limitation: Secular trends in screening, smoking, and viral co-infections were not evaluated.

Conclusion: Cumulative cancer incidence by age 75 years, approximating lifetime risk in persons with HIV, may have clinical utility in this population. The high cumulative incidences by age 75 years for Kaposi sarcoma, non-Hodgkin lymphoma, and lung cancer support early and sustained antiretroviral therapy and smoking cessation.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Cumulative cancer incidence by calendar era and cancer type for HIV-infected subjects with age as the time scale, NA-ACCORD, 1996–2009
KS, Kaposi sarcoma; NHL, Non-Hodgkin’s lymphoma; HL, Hodgkin lymphoma. Cumulative incidence (i.e., cancer risk) curves for calendar eras 1996–1999 (light gray dash-dot line), 2000–2004 (dark gray dash line), and 2005–2009 (black solid line), were obtained using non-parametric estimators for competing risk events. Numbers associated with curves represent cumulative incidence (%) by age 75 years; *P<0.05 compared with reference (1995–1999 era); ** P<0.01 compared with reference (1995–1999 era).
Figure 2
Figure 2. Cumulative cancer incidence by calendar era and cancer type for uninfected subjects with age as the time scale, NA-ACCORD, 1996–2009
KS, Kaposi sarcoma; NHL, Non-Hodgkin’s lymphoma; HL, Hodgkin lymphoma. Cumulative incidence (i.e., cancer risk) curves for calendar eras 1996–1999 (light gray dash-dot line), 2000–2004 (dark gray dash line), and 2005–2009 (black solid line), were obtained using non-parametric estimators for competing risk events. Numbers associated with curves represent cumulative incidence (%) by age 75 years; *P<0.05 compared with reference (1995–1999 era); ** P<0.01 compared with reference (1995–1999 era).

Comment in

Similar articles

Cited by

References

    1. Samji H, Cescon A, Hogg RS, Modur SP, Althoff KN, Buchacz K, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One. 2013;8(12):e81355. - PMC - PubMed
    1. Wada N, Jacobson LP, Cohen M, French A, Phair J, Munoz A. Cause-specific life expectancies after 35 years of age for human immunodeficiency syndrome-infected and human immunodeficiency syndrome-negative individuals followed simultaneously in long-term cohort studies, 1984–2008. Am J Epidemiol. 2013;177(2):116–25. - PMC - PubMed
    1. Justice AC. HIV and aging: time for a new paradigm. Curr HIV/AIDS Rep. 2010;7(2):69–76. - PubMed
    1. Shiels MS, Pfeiffer RM, Gail MH, Hall HI, Li J, Chaturvedi AK, et al. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst. 2011;103(9):753–62. - PMC - PubMed
    1. Guiguet M, Boue F, Cadranel J, Lang JM, Rosenthal E, Costagliola D. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol. 2009;10(12):1152–9. - PubMed

Publication types

Grants and funding